Agenus Inc (AGEN)

[H2R]

AGEN rGBM Ph II: Futility

http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11411350&type=HTML&symbol=AGEN&companyName=Agenus+Inc.&formType=8-K&dateFiled=2017-02-21

Item 7.01 Regulation FD Disclosure.
On February 17, 2017, the Alliance for Clinical Trials in Oncology (the “Alliance”), a cooperative group of the National Cancer Institute, notified Agenus Inc. that the Alliance’s Data and Safety Monitoring Board (“DSMB”) performed an interim analysis for futility of the Phase II trial of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination with bevacizumab in patients with surgically resectable recurrent glioblastoma multiforme. The interim analysis suggested that the trial is unlikely to demonstrate that the vaccine in combination with bevacizumab will lead to a better survival than bevacizumab as a monotherapy. Therefore, upon the DSMB’s recommendation, the accrual for the trial has been closed.